\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{Comparison of SARS-CoV-2 Omicron nucleic acid test for COVID-19
infection with real-time RT-PCR using different nasopharyngeal swabs}



\author[1]{Sujuan Li}%
\author[1]{Yuanhang Zhang}%
\author[1]{Peng cheng Tong}%
\author[1]{Wei Yang}%
\affil[1]{Hangzhou Hospital of Traditional Chinese Medicine}%


\vspace{-1em}



  
  \date{May 22, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
\textbf{Background:} A new one SARS-CoV-2 Variant of Concern (VoC),
Omicron, was born in a world weary of COVID-19, which anger and
frustration with the pandemic was widespread, with wide-ranging negative
impacts on health, social and economic well-being. The Omicron variant,
which main types was BA5.2and BF.7 in China, in December 2022 to January
2023 leaded to off-target of the S and N genes, and the kits used were
not adequately and independently evaluated when these agents are studied
and developed. To ensure the accuracy of coronavirus test results,
performance verification of commercial Real-Time quantitative PCR
(RT-qPCR) was required. \textbf{Objective:} We performed a clinical
evaluation for two Real Time SARS-CoV-2 assay, and to verify them based
on different detection reagents and different clinical specimens.
\textbf{Methods:} We performed clinical evaluations of two existing
Chinese SARS-CoV-2 RT-qPCR kits COVID-19 nucleic acid detection kits
(e-Diagnostic Biomedical, Wuhan, China) and 2019-nCoV nucleic acid
diagnostic kits (Fosun Biotechnology, Shanghai, China) using BSD (
Bondson) (Guangzhou Bondson Biotechnology Co. Ltd.;batch number
2022101), quality controls provided by the inspection center and a large
number of clinically confirmed specimens. Overall, through the BDS
performance verification reference product kit, It was best used to
verify the performance of the reagent through a large number of clinical
specimens for further verification. \textbf{Results:} The coincidence
rate for Fosun and e-Diagnostic kits were individually 95\% and 100\%.
Verified that the detection limit for Fosun and e-Diagnostic kits was
300copies/mL. All were below the detection limit for Fosun reagent was
300copies/mL. e-Diagnostic was 500copies/mL. Fosun had the largest CV
for ORF1ab and N gene at the the detection limit
concentration(4.80\%,3.49\%), while e-Diagnostic had the smaller
(0.93\%,1.10\%). Negative results were tested in cross-reactivity.
During the verification of clinical samples, sequencing analyses had
shown that Fosun single gene miss rate was relatively high, especially
ORF1ab, followed by N gene miss rate. we survey that all N genes were
detected in clinical specimens, ,ORFab dropout (i.e., a negative/low
result) occurred in (10.8\%) of 225 Omicron variant.
\textbf{Conclusions:} Our results endorse the use of these two
commercial kits for the diagnosis of SARS-CoV-2 in China, as their
clinical performance has been fully validated by a large number of
clinically confirmed cases.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`Manuscript - with author details (2).docx`  available at \url{https://authorea.com/users/632385/articles/651192-comparison-of-sars-cov-2-omicron-nucleic-acid-test-for-covid-19-infection-with-real-time-rt-pcr-using-different-nasopharyngeal-swabs}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-1/Fig-1}

\end{center}
\end{figure}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-2/Fig-2}

\end{center}
\end{figure}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-3/Fig-3}

\end{center}
\end{figure}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-4/Fig-4}

\end{center}
\end{figure}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-5/Fig-5}

\end{center}
\end{figure}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-6/Fig-6}

\end{center}
\end{figure}

\textbf{Hosted file}

\verb`table.docx`  available at \url{https://authorea.com/users/632385/articles/651192-comparison-of-sars-cov-2-omicron-nucleic-acid-test-for-covid-19-infection-with-real-time-rt-pcr-using-different-nasopharyngeal-swabs}

\selectlanguage{english}
\FloatBarrier
\end{document}

